全文获取类型
收费全文 | 2046篇 |
免费 | 153篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 111篇 |
妇产科学 | 30篇 |
基础医学 | 234篇 |
口腔科学 | 12篇 |
临床医学 | 286篇 |
内科学 | 432篇 |
皮肤病学 | 25篇 |
神经病学 | 222篇 |
特种医学 | 37篇 |
外科学 | 187篇 |
综合类 | 14篇 |
一般理论 | 4篇 |
预防医学 | 142篇 |
眼科学 | 16篇 |
药学 | 152篇 |
中国医学 | 3篇 |
肿瘤学 | 275篇 |
出版年
2023年 | 25篇 |
2022年 | 14篇 |
2021年 | 45篇 |
2020年 | 48篇 |
2019年 | 67篇 |
2018年 | 78篇 |
2017年 | 60篇 |
2016年 | 63篇 |
2015年 | 60篇 |
2014年 | 82篇 |
2013年 | 111篇 |
2012年 | 187篇 |
2011年 | 163篇 |
2010年 | 98篇 |
2009年 | 71篇 |
2008年 | 121篇 |
2007年 | 122篇 |
2006年 | 121篇 |
2005年 | 128篇 |
2004年 | 130篇 |
2003年 | 102篇 |
2002年 | 88篇 |
2001年 | 14篇 |
2000年 | 14篇 |
1999年 | 19篇 |
1998年 | 16篇 |
1997年 | 11篇 |
1996年 | 11篇 |
1995年 | 17篇 |
1994年 | 11篇 |
1993年 | 10篇 |
1992年 | 9篇 |
1991年 | 11篇 |
1990年 | 7篇 |
1989年 | 9篇 |
1988年 | 6篇 |
1987年 | 6篇 |
1986年 | 11篇 |
1985年 | 9篇 |
1984年 | 3篇 |
1983年 | 6篇 |
1982年 | 5篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1978年 | 4篇 |
1977年 | 5篇 |
1973年 | 2篇 |
1972年 | 1篇 |
1966年 | 1篇 |
1960年 | 1篇 |
排序方式: 共有2210条查询结果,搜索用时 15 毫秒
1.
Ziad Saad Derrek Hibar Maggie Fedgchin Vanina Popova Maura L Furey Jaskaran B Singh Hartmuth Kolb Wayne C Drevets Guang Chen 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(9):549
BackgroundAt ketamine and esketamine doses at which antidepressant doses are achieved, these agents are relatively selective, noncompetitive, N-methyl-D-aspartate receptor antagonists. However, at substantially higher doses, ketamine has shown mu-opioid receptor (MOR–gene symbol: OPRM1) agonist effects. Preliminary clinical studies showed conflicting results on whether naltrexone, a MOR antagonist, blocks the antidepressant action of ketamine. We examined drug-induced or endogenous MOR involvement in the antidepressant and dissociative responses to esketamine by assessing the effects of a functional single nucleotide polymorphism rs1799971 (A118G) of OPRM1, which is known to alter MOR agonist-mediated responses.MethodsParticipants with treatment-resistant depression from 2 phase III, double-blind, controlled trials of esketamine (or placebo) nasal spray plus an oral antidepressant were genotyped for rs1799971. Participants received the experimental agents twice weekly for 4 weeks. Antidepressant responses were rated using the change in Montgomery–Åsberg Depression Rating Scale (MADRS) score on days 2 and 28 post-dose initiation, and dissociative side effects were assessed using the Clinician-Administered Dissociative-States Scale at 40 minutes post-dose on days 1 and 25.ResultsIn the esketamine + antidepressant arm, no significant genotype effect of single nucleotide polymorphism rs1799971 (A118G) on MADRS score reductions was detected on either day 2 or 28. By contrast, in the antidepressant + placebo arm, there was a significant genotype effect on MADRS score reductions on day 2 and a nonsignificant trend on day 28 towards an improvement in depression symptoms in G-allele carriers. No significant genotype effects on dissociative responses were detected.ConclusionsVariation in rs1799971 (A118G) did not affect the antidepressant response to esketamine + antidepressant. Antidepressant response to antidepressant + placebo was increased in G-allele carriers, compatible with previous reports that release of endorphins/enkephalins may play a role in mediating placebo effect.Trial Registration and NCT02417064; NCT02418585www.clinicaltrials.gov 相似文献
2.
3.
Susanna Zanutto Chiara Maura Ciniselli Antonino Belfiore Mara Lecchi Enzo Masci Gabriele Delconte Massimo Primignani Giulia Tosetti Marco Dal Fante Linda Fazzini Aldo Airoldi Marcello Vangeli Francesca Turpini Giovanni Giuseppe Rubis Passoni Paolo Viaggi Monica Arena Roberta Ilaria Olimpia Motta Anna Maria Cantù Cristiano Crosta Giuseppe De Roberto Francesca Iannuzzi Andrea Cassinotti Valentina Dall'Olio Laura Tizzoni Gabriella Sozzi Emanuele Meroni Luigi Bisanti Marco Alessandro Pierotti Paolo Verderio Manuela Gariboldi 《International journal of cancer. Journal international du cancer》2020,146(4):1164-1173
Colorectal cancer (CRC) screening programs help diagnose cancer precursors and early cancers and help reduce CRC mortality. However, currently recommended tests, the fecal immunochemical test (FIT) and colonoscopy, have low uptake. There is therefore a pressing need for screening strategies that are minimally invasive and consequently more acceptable to patients, most likely blood based, to increase early CRC identification. MicroRNAs (miRNAs) released from cancer cells are detectable in plasma in a remarkably stable form, making them ideal cancer biomarkers. Using plasma samples from FIT-positive (FIT+) subjects in an Italian CRC screening program, we aimed to identify plasma circulating miRNAs that detect early CRC. miRNAs were initially investigated by quantitative real-time PCR in plasma from 60 FIT+ subjects undergoing colonoscopy at Fondazione IRCCS Istituto Nazionale dei Tumori, then tested on an internal validation cohort (IVC, 201 cases) and finally in a large multicenter prospective series (external validation cohort [EVC], 1121 cases). For each endoscopic lesion (low-grade adenoma [LgA], high-grade adenoma [HgA], cancer lesion [CL]), specific signatures were identified in the IVC and confirmed on the EVC. A two-miRNA-based signature for CL and six-miRNA signatures for LgA and HgA were selected. In a multivariate analysis including sex and age at blood collection, the areas under the receiver operating characteristic curve (95% confidence interval) of the signatures were 0.644 (0.607–0.682), 0.670 (0.626–0.714) and 0.682 (0.580–0.785) for LgA, HgA and CL, respectively. A miRNA-based test could be introduced into the FIT+ workflow of CRC screening programs so as to schedule colonoscopies only for subjects likely to benefit most. 相似文献
4.
Mansour Gergi Kara K. Landry Steven Ades Maura Barry Neil A. Zakai Diego Adrianzen Herrera 《The oncologist》2020,25(12):1009-1012
Thrombotic thrombocytopenic purpura (TTP) is a rare but life‐threatening microangiopathic hemolytic anemia characterized by thrombocytopenia, hemolytic anemia, and ischemic organ damage. It is mainly caused by an autoreactive antibody directed at ADAMTS13. Immunotherapy is frequently associated with autoimmune complications in patients with cancer, but only three cases of TTP have been reported, none implicating single treatment with the anti–programmed cell death receptor 1 ligand antibody nivolumab. We present the first identified and reported case of nivolumab‐associated TTP in a 51‐year‐old woman with stage IIIc anal carcinoma who achieved complete response following chemoradiation and received adjuvant nivolumab as part of a randomized clinical trial. Twelve weeks into treatment, she presented with dark urine, progressive fatigue, and headache. TTP diagnosis was based on laboratory evidence of hemolytic anemia, thrombocytopenia, and ADAMTS13 activity of 9% associated with an inhibitor. She was treated with daily plasma exchange and oral prednisone and responded well to treatment, with platelet counts over 100 K/cmm within 4 days. We reviewed and summarized data from all reported cases of TTP associated with cancer immunotherapy. We provide guidance on identification and management of this devastating hematologic complication, focusing on the importance of early recognition, as most patients achieve complete recovery with appropriate treatment.Key Points
- Thrombotic thrombocytopenic purpura (TTP) was originally excluded from previous reviews of hematologic immune‐related adverse events; however, several cases have been reported in the past 2 years in patients treated with either single agent or combination of cytotoxic T‐lymphocyte–associated antigen 4 and the programmed cell death receptor 1 (PD‐1) or the PD‐1 ligand inhibitors.
- Although rare, TTP is a life‐threatening condition that could be challenging to diagnose, and early recognition is key as delayed treatment is associated with significant increase in mortality.
- The pathophysiology of immunotherapy‐induced TTP is likely related to autoimmune inhibition of ADAMTS13; the addition of prednisone and rituximab to urgent plasmapheresis appears to be effective and should be part of the up‐front management for these patients.
5.
Joshi Gagan DiSalvo Maura Faraone Stephen V. Wozniak Janet Fried Ronna Galdo Maribel Belser Abigail Hoskova Barbora Dallenbach Nina T. De Leon Melissa F. Biederman Joseph 《European child & adolescent psychiatry》2020,29(6):791-801
European Child & Adolescent Psychiatry - The objective of this study was to investigate the stability and predictive utility of autistic traits (ATs) in youth with... 相似文献
6.
7.
Nicastro Nicolas Rodriguez Patricia Vazquez Malpetti Maura Bevan-Jones William Richard Simon Jones P. Passamonti Luca Aigbirhio Franklin I. O’Brien John T. Rowe James B. 《Journal of neurology》2020,267(2):341-349
Journal of Neurology - Progressive supranuclear palsy (PSP) is characterized by deposition of straight filament tau aggregates in the grey matter (GM) of deep nuclei and cerebellum. We examined the... 相似文献
8.
9.
Huang Sicong He Xintong Doyle Tracy J. Zaccardelli Alessandra Marshall Allison A. Friedlander H. Maura Blaustein Rachel B. Smith Elisabeth A. Cui Jing Iannaccone Christine K. Mahmoud Taysir G. Weinblatt Michael E. Dellaripa Paul F. Shadick Nancy A. Sparks Jeffrey A. 《Clinical rheumatology》2020,39(4):1371-1372
Clinical Rheumatology - The publisher regrets that the two sections under the Results omitted inadvertently on the original published version of the above article. 相似文献
10.
Thaís Helena Gasparoto Tatiana Salles de Souza Malaspina José Humberto Damante Edgard Franco de Mello Jr Maura Rosane Valério Ikoma Gustavo Pompermaier Garlet Maria Renata Sales Nogueira Costa Karen Angélica Cavassani João Santana da Silva Ana Paula Campanelli 《Journal of oral pathology & medicine》2014,43(10):754-760